---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277468"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:15:52.240514+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma Q3 net loss $0.07/sh; ImmunoScape deal $15M upfront; new CEO

## Summary
- Q3 net loss $7.45M ($0.07 EPS); revenue $2.15M (down 36% YoY); cash $11.7M (down 48% from Dec 2024).
- Collaboration with ImmunoScape: upfront total $15M ($10M in Q4 2025, $5M in Nov 2026) plus 40% equity stake.
- Usman Azam appointed President & CEO effective Sep 29; leadership transition to advance autoimmune asset CUE-401.
- CUE-101+pembrolizumab in HPV+ HNSCC: 50% ORR, 88% 12-month OS, median OS 32.7 months.
- R&D spend $4.8M (down 49% YoY); G&A $4.9M (up 72% YoY) due to severance and professional fees.

## SEC filing metadata
- accession: 0001193125-25-277468
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312525277468/0001193125-25-277468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312525277468/cue-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277468
- JSON: https://secwatch.observer/filing/0001193125-25-277468.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.